Author

L. M. Bradley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. B. Palete· 1 shared A. R. Campos· 1 shared A. Rao· 1 shared C. J. Stairiker· 1 shared D. C. Otero· 1 shared E. Ruppin· 1 shared E. S. Wang· 1 shared E.-A. Bae· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. B. Palete

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Control of alveolar macrophage differentiation by Siah1a/2 ubiquitin ligases limits carcinogen-induced lung adenocarcinoma

M. Scortegagna, Y. Du, L. M. Bradley, K. Wang, E. Ruppin, R. Murad, Z. A. Ronai

This study shows that Siah1a/2 ubiquitin ligases regulate alveolar macrophage differentiation, and their loss promotes lung adenocarcinoma by increasing immature macrophages and pro-tumorigenic inflammation.

bioRxiv · Sep 14, 2022Cancer Biology

PSGL-1 directs early TCR signaling to repress metabolism and promote T cell exhaustion by modulating the TCF-1/TOX axis in CD8+ T cells.

J. L. Hope, D. C. Otero, E.-A. Bae, C. J. Stairiker, A. B. Palete, H. A. Faso, M. L. Henriquez, H. Seo, X. Lei, E. S. Wang, R. Tinoco, A. R. Campos, J. Yin, P. D. Adams, A. Rao, L. M. Bradley

This study shows PSGL-1 modulates TCF-1/TOX axis to repress metabolism and promote T cell exhaustion in CD8+ T cells, making it a therapeutic target for PD-1/PD-L1 resistant tumors.

bioRxiv · Jan 24, 2022 · PreprintImmunology